| Literature DB >> 35732969 |
Steven Belenko1, Michael Dennis2, Matthew Hiller3, Juliette Mackin4, Chelsey Cain3, Doris Weiland3, Barbara Estrada2, Raanan Kagan5.
Abstract
Juvenile Drug Treatment Courts (JDTC) emerged in the mid-1990s as a potential solution to concern about substance use among youth in the juvenile justice system (JJS). Despite substantial research, findings on the JDTC effectiveness for reducing recidivism and substance use remain inconsistent, hampered by methodological problems. In 2016, the Office of Juvenile Justice and Delinquency Prevention published research-based JDTC Guidelines for best practices, and funded technical assistance for implementation and a multisite national outcomes study among JDTCs implementing the Guidelines. Ten sites were originally selected for this study, with a JDTC and Traditional Juvenile Court (TJC) participating. In two sites, moderate- to high-risk youth were randomized to JDTC or TJC, and in eight sites, a regression discontinuity design assigned moderate- to high-risk youth to JDTC, and other youth to TJC. Findings from four sites with sufficient cases and follow-up rates indicated that JDTCs reduced cannabis use, increased access to mental health services, and reduced recidivism. However, the effects were small to moderate, with positive impacts mainly observed among high-risk youth. The impacts of JDTCs may have been attenuated because Guidelines implementation was inconsistent across courts, and some TJCs implemented elements of the Guidelines, blurring the distinction between JDTCs and TJCs.Entities:
Mesh:
Year: 2022 PMID: 35732969 PMCID: PMC9217114 DOI: 10.1007/s11414-022-09805-4
Source DB: PubMed Journal: J Behav Health Serv Res ISSN: 1094-3412 Impact factor: 1.475
Fig. 1CONSORT diagram
Sample characteristics — all study sites (% unless otherwise noted)
| Random assignment | Regression discontinuity | Total | |||
|---|---|---|---|---|---|
| JDTC ( | TJC ( | JDTC ( | TJC ( | ||
| Gender | |||||
| Female | 5.1 | 5.1 | 28.4 | 30.1 | 24.3 |
| Male | 94.9 | 94.9 | 71.6 | 69.9 | 75.4 |
| Race/Ethnicity | |||||
| Black | 43.6 | 33.3 | 30.0** | 41.9 | 35.5 |
| White | 5.1 | 5.1 | 49.5 | 30.1 | 34.8 |
| Hispanic | 28.2 | 35.9 | 3.5 | 5.9 | 9.7 |
| Mixed | 20.5 | 23.1 | 16.0 | 21.3 | 18.8 |
| Another race/ethnicity | 2.6 | 2.6 | 1.0 | 0.7 | 1.1 |
| Mean age | 15.8 | 15.5 | 15.2 | 15.4 | 15.5 |
| Mean last grade completed | 8.9 | 8.5 | 8.7 | 8.8 | 8.8 |
| Delinquency history | |||||
| Mean no. of times arrested and charged lifetime | 2.6 | 4.2 | 3.0*** | 1.5 | 2.6 |
| Ever pushed, grabbed, shoved someone | 87.2 | 76.9 | 89.1*** | 51.5 | 75.5 |
| Ever taken something from store w/o paying | 69.2 | 64.1 | 65.7*** | 30.6 | 54.5 |
| Ever sold/distributed/made illegal drugs | 48.7 | 56.4 | 35.3*** | 7.5 | 29.5 |
| Ever destroyed property | 43.6 | 46.2 | 46.3*** | 20.1 | 27.5 |
| Recidivism risk | |||||
| Low | 0.0 | 0.0 | 0.0*** | 25.4 | 8.2 |
| Moderate | 33.3 | 25.6 | 36.3 | 67.9 | 45.3 |
| High | 28.2 | 20.5 | 29.9 | 6.7 | 21.3 |
| Very high | 38.5 | 53.8 | 33.8 | 0.0 | 25.2 |
| Substance use (past 90 days) | |||||
| % cannabis use | 97.4* | 84.6 | 91.5*** | 40.4 | 74.7 |
| Avg. no. of days cannabis use (SD) | 55.0 (28.3)* | 42.2 (28.1) | 39.4 (30.4)*** | 9.5 (21.0) | 31.6 (31.5) |
| % alcohol or non-cannabis drug use | 46.2 | 33.3 | 47.8*** | 11.2 | 34.7 |
| % ever received AOD treatment | 43.6 | 35.9 | 21.9** | 7.5 | 20.6 |
| Mental health indicators | |||||
| Bothered by MH problems past 90 days | 64.1 | 59.0 | 69.3* | 43.3 | 59.4 |
*p < .05, **p < .01, ***p < .001
Substance use outcomes
| Random assignment | JDTC ( | TJC ( | ||||
| Baseline | 6 months f/u | Change | Baseline | 6 months f/u | Change | |
| % reporting cannabis use, past 90 days | 100.0 | 66.7 | − 33.3 | 100.0 | 82.6 | − 17.4 |
| Avg. days cannabis use, past 90 days (SD) (including zero) | 63.7 (SD 21.7) | 34.7 (SD 38.9) | − 29.0 | 52.0 (SD 22.4) | 39.9 (SD 31.7) | − 12.1 |
| % youth no AOD use other than cannabis, past 90 days | 9.5 | 14.3 | + 4.8 | 17.4 | 21.7 | + 4.3 |
| Regression discontinuity | JDTC ( | TJC ( | ||||
| Baseline | 6 months f/u | Change | Baseline | 6 months f/u | Change | |
| % youth reporting cannabis use, past 90 days | 96.2 | 64.6 | − 31.6 | 34.6 | 22.0 | − 12.6 |
| Avg. days cannabis use, past 90 days (SD) (including zero) | 42.15 (SD 30.41) | 23.55 (SD 29.65) | − 18.6*** | 10.17 (SD 22.77) | 8.65 (SD 20.50) | − 1.42 |
| % youth reporting AOD use other than cannabis, past 90 days | 48.5 | 36.2 | − 12.3 | 13.4 | 11.0 | − 2.4 |
*p < .05, **p < .01, ***p < .001
Effect of court type (JDTC versus TJC) on days of cannabis use at 6-month follow-up for the three RD sites combined
| Backward stepwise regressiona | SE | 95% LCL | 95% UCL | Sig | |||
|---|---|---|---|---|---|---|---|
| Variables in model | |||||||
| Constant | 13.115 | 4.201 | 4.814 | 21.416 | 3.122 | .002 | |
| Baseline days MJ use in past 90 | .171 | .076 | .019 | .322 | .179 | 2.231 | .027 |
| Baseline lifetime arrests | 1.358 | .709 | − .043 | 2.759 | .153 | 1.916 | .057 |
| Variables excluded | |||||||
| Court type (JDTC vs. TJC) | .036 | .424 | .672 | ||||
| Baseline substance use problems, lifetime (L, M, H)b | − .044 | − .532 | .595 | ||||
| Initiated treatment | − .040 | − .471 | .638 | ||||
| Gender | − .048 | − .596 | .552 | ||||
| Mental health problems, past 90 days at 6 months | .071 | .885 | .377 | ||||
| Final model | |||||||
aListwise missing exclusion
bGAIN Substance Disorder Screener, grouped (low = 0, moderate = 1–2, high = 3–5)
Mental health outcomes, past 90 days
| JDTC ( | TJC ( | |||||
| Baseline | 6 month f/u | Change | Baseline | 6 month f/u | Change | |
| Received outpatient MH treatment | 9.5 | 23.8 | + 14.3 | 8.7 | 27.3 | + 20.3 |
| On MH medication | 0.0 | 9.5 | + 9.5 | 4.3 | 22.7 | + 18.4 |
| Bothered by MH problems | 61.9 | 66.7 | + 4.8 | 69.6 | 81.8 | + 12.2 |
| Mean no. of MH symptoms | 2.6 | 2.7 | + 0.1 | 2.7 | 3.1 | + 0.4 |
| JDTC ( | TJC ( | |||||
| Baseline | 6 month f/u | Change | Baseline | 6 month f/u | Change | |
| Received outpatient MH treatment | 21.7 | 60.5 | + 38.8*** | 17.1 | 22.4 | + 5.3 |
| On MH medication | 13.8 | 19.4 | + 5.6 | 14.6 | 14.3 | − 0.3 |
| Bothered by MH problems | 76.6 | 71.2 | − 5.4*** | 50.0 | 51.9 | + 1.9 |
| Mean no. of MH symptoms | 3.2* | 3.5** | + 0.3 | 2.4 | 2.4 | 0.0 |
*p < .05, **p < .01, ***p < .001
Rearrests in 12 months after assignment by design, site, and court typea
| Design | Random Assignment | Regression discontinuity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Site | Site A | Site C | Site H | Site I | Across 4 sites | |||||||||
| Court type (number of participants) | TJC ( | JDTC ( | TJC ( | JDTC ( | TJC ( | JDTC ( | TJC ( | JDTC ( | TJC ( | JDTC ( | ||||
| Expected rearrest rateb | 74% | 72% | 52% | 72% | 50% | 72% | 51% | 69% | 55% | 72% | ||||
| Observed rearrest rate | 60% | 32% | 27% | 59% | 61% | 68% | 16% | 25% | 34% | 54% | ||||
| Difference (Obs.–Exp.) | − 14% | − 40% | − 25% | − 13% | + 11% | − 4% | − 35% | − 44% | − 21% | − 18% | ||||
| Relative difference (JDTC-TJC) | − 9 | + 9.10 | ||||||||||||
| Cohen’s D | + 0.19 | |||||||||||||
| + 2.76 | ||||||||||||||
| d.f | 302 | |||||||||||||
| 0.90 | ||||||||||||||
| Mean rank % (low is good) | 57% v 45% | 54% v 49% | 67% vs 45% | 58% vs 32% | ||||||||||
| Mann–Whitney based | − 1.4 | − 0.7 | ||||||||||||
| 0.172 | 0.484 | |||||||||||||
aBold means that the probability of the t-test or Z-rank values is less than 0.05 and/or that the Cohen’s effect size is greater than − 0.20 (i.e., JDTC reduced recidivism from expected more than TJC)
bBased on national data
Fig. 2Differences between predicted and observed probability of 12-month recidivism by court type (combined RA and RD sites). Rearrest probability differences are binned. Greater reductions in re-arrest probability (i.e., more negative observed-minus-predicted differences) were observed in JDTCs (mean rate percentile = 47%) than in TJCs (55%), Zrank = − 2.4, p < .05